



February 17, 2023

To

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 - 22721919

Ref: Aragen Life Sciences Limited

Scrip Code: 973783

ISIN: INE483107010

Sub: Publication of Extract of Financial Results in an English national daily newspaper

In compliance with Regulation 52 (8) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company has, on Wednesday, 15th February 2023, published in The Economic Times, an English national daily newspaper, the extract of the Financial Results for the quarter and nine months ended 31st December 2022. A copy of the newspaper cutting is enclosed herewith.

Please take on your records.

For Aragen Life Sciences Limited

KASTURI Digitally signed by
KASTURI
RAMAKRISHNA
RAMAKRISHNA
Date: 2023.02.17
HNA 17:47:49 +05'30'

Ramakrishna Kasturi

Company Secretary & Compliance Officer

Note: The Shareholders of the Company, at their Extraordinary General Meeting held on 27th January 2023, approved the Conversion of the Company from a Private Limited to a Public Limited and the relevant alterations to the MOA and AOA thereon. Pursuant to Section 14 of Companies Act, 2013, the Company ceased to be a Private Limited Company w.e.f. the aforesaid date. The ROC Certificate pursuant to the Conversion is yet to be obtained.

ARAGEN LIFE SCIENCES PRIVATE LIMITED

CIN: U74999TG2000PTC035826

Registered and Corporate Office: Plot 28A, IDA Nacharam, Hyderabad
Telangana-500076, India

Tel: +91 40 6692 9999 F: +91 40 6692 9900

Email id: compliances@aragen.com, website:www.aragen.com

**Extract of standalone financial results for the quarter and nine months ended 31 December 2022**
(₹ in million)

S. No.	Particulars	Quarter ended			Half year ended		Year ended
		31 December 2022	30 September 2022	31 December 2021	31 December 2022	31 December 2021	31 March 2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	4019.87	3917.07	3220.39	11719.75	9177.70	12359.68
2	Net Profit / (Loss) for the period (before tax, Exceptional and/or Extraordinary items)	801.87	865.31	748.18	2381.01	2108.69	2773.55
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	801.87	865.31	748.18	2381.01	2108.69	2773.55
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	602.97	635.42	565.29	1774.89	1593.32	2109.78
5	Total Comprehensive Income for the period	644.35	412.35	624.77	1295.46	1653.06	2120.18
6	Paid up Equity Share Capital	681.38	681.38	681.38	681.38	681.38	681.38
7	Reserves (excluding Revaluation Reserve)	-	-	-	-	-	9748.52
8	Securities Premium Account	391.33	391.33	391.33	391.33	391.33	391.33
9	Net worth	11149.26	10499.93	9939.44	11149.26	9939.44	10429.90
10	Paid up Debt Capital/ Outstanding Debt	5119.30	4898.69	3588.83	5119.30	3588.83	5204.54
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-
12	Debt Equity Ratio*	0.46	0.47	0.36	0.46	0.36	0.50
13	Earnings Per Share (EPS) (Face value of ₹ 10 each fully paid) *						
	Basic EPS (Rs)	2.98	3.15	2.80	8.79	7.92	10.47
	Diluted EPS (Rs)	2.95	3.11	2.77	8.68	7.83	10.35
14	Capital Redemption Reserve	3.36	3.36	3.36	3.36	3.36	3.36
15	Debenture Redemption Reserve	200.00	200.00	NA	200.00	NA	200.00
16	Debt Service Coverage Ratio*	4.57	4.03	7.61	3.99	6.04	4.89
17	Interest Service Coverage Ratio*	9.35	9.41	17.45	8.88	17.39	13.19

*EPS and ratios are not annualised for the quarter/nine months ended.

Notes:

- The above is an extract of the detailed format of quarterly and year-to-date financial results filed with the stock exchange under Regulation 52 of the Listing Regulations as the company's debt securities are listed. The full format of the quarterly and year-to-date financial results are available on the websites of the stock exchange- BSE Limited at www.bseindia.com and the company at www.aragen.com.
- For the other line items referred to in Regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the stock exchange, BSE Limited, and can be accessed at www.bseindia.com.
- The above standalone financial results for the quarter and nine months ended 31 December 2022 which are published in accordance with Regulation 52 of the LODR Regulations, have been reviewed and recommended by the Audit Committee on 12th February 2023, and approved by the Board of Directors at its meeting held on 13th February 2023.
- The Company has started publishing quarterly results from the quarter ended 31 March 2022 and hence quarterly figures for the quarter ended 31 December 2021 were neither reviewed nor subjected to an audit, however, the management has exercised necessary due diligence to ensure that the financial results for this period provide a true and fair view of the Company's affairs.
- Pursuant to the resolution passed by the Directors of the Company on 25 January 2023 and approved by the shareholders at the extraordinary general meeting held on 27 January 2023, the Company has been converted from a Private Limited Company to a Public Limited Company and the Company ceased to be Private company as per Section 14 of the Companies Act, 2013. The Company is in the process of obtaining a fresh certificate of incorporation consequent upon conversion of the Company from the Registrar of Companies, Ministry of Corporate Affairs.

For Aragen Life Sciences Private Limited

Sd/-

Manmahesh Kantipudi

Whole Time Director & CEO

DIN: 05241166

Date: 13th February 2023

Place: Hyderabad